Naslov
Efficacy of concurrent application of carbamazepine and oxcarbazepine in the treatment of pharmacoresistant epilepsy patients – a retrospective study

Autori
Hajnsek, Sanja ; Sulentic, Vlatko ; Kovacevic, Ivana ; Bujan Kovac, Andreja ; Nankovic, Sibila ; Petelin Gadze, Zeljka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Epilepsia / - , 2014, 48-48

Skup
11th European Congress on Epileptology

Mjesto i datum
Stockholm, Švedska, 29.06.2014. - 03.07.2014

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
pharmacoresistant epilepsy; carbamazepine; oxcarbazepine

Sažetak
Carbamazepine (CBZ) and oxcarbazepine (OXC) are both first line antiepileptic drugs (AEDs) for partial and generalized seizures with focal onset. However, from the pharmacodynamic and pharmacokinetic point of view, CBZ and OXC are not identical medications. As CBZ and OXC nonetheless differ, their co-administration should be considered in pharmacoresistant patients. We have performed a retrospective study with the aim to determine the efficacy of concurrent application of CBZ and OXC in the treatment of pharmacoresistant patients with partial epilepsy. 24 patients, in whom former application of combination of other first and second line AEDs for partial seizures had been ineffective, were included in the study. The mean follow-up time was 23.50±8.81 months. The majority (72.9%) had symptomatic epilepsy and the average disease duration was 22.29±15.30 years. The efficacy was estimated 6 months after therapy introduction. The number of seizures before combined CBZ + OXC therapy introduction was higher (8.47±8.52) compared to the number of seizures after therapy introduction (4.49±5.44) and the difference was statistically significant (p=0.015). The combination of OXC and CBZ has yielded improvement. In 50% of patients the reduction of seizures was registered (from 25-99%). Clinically significant seizure reduction for ≥50% was observed in 29.17% of patients. The most common side effects were drowsiness, vertigo and hyponatremia that was not clinically significant. Our study has demonstrated the efficacy of combined CBZ and OXC therapy, notably in pharmacoresistant partial epilepsy, with recommendation of using lower doses, which leads to better tolerance of both drugs and avoidance of side effects.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA